VALNEVA Announces Approval of an EB66(R)-based Prototype Influenza Vaccine in Japan

March 26, 2015 02:56 ET | Source: VALNEVA VALNEVA

LYON, France, March 26, 2015 (GLOBE NEWSWIRE) -- The vaccine was developed by the Chemo-Sero Therapeutic Research Institute (Kaketsuken) in collaboration with GlaxoSmithKline using Valneva's EB66^® cell line, this represents a potential of 80 million vaccine doses to be produced in the event of a pandemic.

To download the full press release, please click on the following icon:

2015_03_26 Valneva CC Prototype Flu Vaccine ENG http://hugin.info/143334/R/1906344/678670.pdf
2015_03_26 Valneva CC Prototype Flu Vaccine FRA http://hugin.info/143334/R/1906344/678672.pdf
2015_03_26 Valneva CC Prototype Flu Vaccine GER http://hugin.info/143334/R/1906344/678673.pdf

HUG#1906344

Contact Data

            Florence Hocdee- Leroy
T: +33 (0)228 07 37 10
M: +33 642 04 42 14

Teresa Pinzolits
T: +43-1-206 20-1116
M: +43 676 845567357

Contact